statistiche ricercatore

PASSAMONTI, FRANCESCO

Distribuzione geografica

Continente	#
NA - Nord America	22.206
EU - Europa	10.072
AS - Asia	5.183
SA - Sud America	841
AF - Africa	67
Continente sconosciuto - Info sul continente non disponibili	13
OC - Oceania	7
Totale	38.389

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	22.047
IT - Italia	5.555
SG - Singapore	1.744
UA - Ucraina	1.564
TR - Turchia	1.023
CN - Cina	748
VN - Vietnam	727
BR - Brasile	702
SE - Svezia	698
HK - Hong Kong	619
IE - Irlanda	613
DE - Germania	401
GB - Regno Unito	359
FI - Finlandia	322
RU - Federazione Russa	255
CA - Canada	95
FR - Francia	69
IN - India	60
JP - Giappone	55
AR - Argentina	52
MX - Messico	45
BD - Bangladesh	42
AT - Austria	35
NL - Olanda	33
CZ - Repubblica Ceca	30
PL - Polonia	30
EC - Ecuador	28
ES - Italia	27
IQ - Iraq	27
ZA - Sudafrica	20
ID - Indonesia	19
PK - Pakistan	16
LT - Lituania	15
SA - Arabia Saudita	14
BE - Belgio	13
CO - Colombia	12
EU - Europa	11
VE - Venezuela	11
CL - Cile	10
UZ - Uzbekistan	10
EG - Egitto	9
HU - Ungheria	9
KE - Kenya	9
MY - Malesia	9
IR - Iran	8
KR - Corea	8
PE - Perù	8
BG - Bulgaria	7
JO - Giordania	7
MA - Marocco	7
PY - Paraguay	7
UY - Uruguay	7
AE - Emirati Arabi Uniti	6
CH - Svizzera	6
KZ - Kazakistan	6
NO - Norvegia	6
NP - Nepal	6
RS - Serbia	6
TW - Taiwan	6
ET - Etiopia	5
IL - Israele	5
TN - Tunisia	5
AU - Australia	4
AZ - Azerbaigian	4
SN - Senegal	4
TH - Thailandia	4
BA - Bosnia-Erzegovina	3
CR - Costa Rica	3
DO - Repubblica Dominicana	3
DZ - Algeria	3
GR - Grecia	3
HN - Honduras	3
LB - Libano	3
NZ - Nuova Zelanda	3
RO - Romania	3
TT - Trinidad e Tobago	3
AL - Albania	2
AO - Angola	2
BO - Bolivia	2
DK - Danimarca	2
GY - Guiana	2
KW - Kuwait	2
MD - Moldavia	2
OM - Oman	2
PA - Panama	2
SK - Slovacchia (Repubblica Slovacca)	2
A2 - ???statistics.table.value.countryCode.A2???	1
BS - Bahamas	1
BW - Botswana	1
CI - Costa d'Avorio	1
GT - Guatemala	1
JM - Giamaica	1
KN - Saint Kitts e Nevis	1
LU - Lussemburgo	1
MN - Mongolia	1
NI - Nicaragua	1
PS - Palestinian Territory	1
PT - Portogallo	1
QA - Qatar	1
SD - Sudan	1
Totale	38.388

Salva come PNG Salva come JPEG

Città	#
Milan	4.204
Fairfield	3.291
Woodbridge	2.767
Houston	2.073
Ashburn	1.825
Ann Arbor	1.578
Jacksonville	1.336
Seattle	1.332
Cambridge	1.176
Wilmington	1.124
Singapore	864
Chandler	678
Hong Kong	611
Dublin	610
Dallas	548
Princeton	525
Dearborn	479
Izmir	473
Nyköping	365
Boardman	333
Dong Ket	271
Rome	238
Beijing	223
San Diego	176
Ogden	133
The Dalles	133
London	97
Los Angeles	96
Como	84
New York	77
Ho Chi Minh City	66
São Paulo	66
Chicago	64
Redmond	64
Washington	64
Santa Clara	53
Hefei	50
Hanoi	48
Kocaeli	48
Munich	44
Nanjing	43
Tokyo	39
Guangzhou	35
Kunming	35
Toronto	34
Helsinki	33
Mexico City	30
Kilburn	29
Norwalk	29
Montreal	27
San Francisco	27
Rio de Janeiro	26
Warsaw	26
Redwood City	25
Brno	24
Brooklyn	24
Columbus	21
Düsseldorf	21
Atlanta	20
Council Bluffs	20
Jinan	20
Ankara	19
Boston	19
Zhengzhou	19
Nanchang	18
Orem	18
Phoenix	18
Salt Lake City	18
San Jose	18
Denver	17
Johannesburg	17
Nuremberg	17
Verona	17
Belo Horizonte	16
Chennai	16
Frankfurt am Main	16
Quito	16
Turku	16
Vienna	16
Poplar	15
Acton	14
Brasília	14
Changsha	14
Brussels	13
Stockholm	13
Amsterdam	12
Curitiba	12
Shenyang	12
Baotou	11
Chiswick	11
Florence	11
Reston	11
Shanghai	11
Chengdu	10
Dhaka	10
Fuzhou	10
Haiphong	10
Tashkent	10
Varese	10
Da Nang	9
Totale	29.429

Salva come PNG Salva come JPEG

Nome	#
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm	273
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence	261
Analysis of three screening methods for the detection of calreticulin gene mutations	247
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.	244
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations	229
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group	228
A gain-of-function mutation of JAK2 in myeloproliferative disorders	223
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis	222
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts	220
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis	219
Mutations and thrombosis in essential thrombocythemia: Prognostic interaction with age and thrombosis history	215
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT.	213
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms	213
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group	213
European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.	211
New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma	209
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.	207
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study	207
Looking for CALR mutations in familial myeloproliferative neoplasms	204
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN	203
ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA	202
A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion	202
Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia	199
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.	197
Mutational status of myeloproliferative neoplasms.	195
Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies	194
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis	194
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.	193
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera	192
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia.	192
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients	191
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.	190
A novel germline JAK2 mutation in familial myeloproliferative neoplasms	189
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera.	189
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia	189
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients	188
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.	185
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms	184
Novel agents in indolent lymphomas	183
European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis: Haematologica 2012;97(3):360-5 - Comment	183
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype.	183
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts	182
It is time to change thrombosis risk assessment for PV and ET?	181
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms.	181
Developments in diagnosis and treatment of essential thrombocythemia	181
Standard care and investigational drugs in the treatment of myelofibrosis	181
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders	180
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.	180
Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma	179
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis	179
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients	178
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia	178
Driver mutations' effect in secondary myelofibrosis: An international multicenter study based on 781 patients	178
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project	178
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs	178
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients	177
Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden	177
TREATMENT OF POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA: THE ROLE OF PIPOBROMAN.	176
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early /prefibrotic primary myelofibrosis.	176
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders	176
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial	176
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group	176
What are RBC-transfusion-dependence and -independence?	175
JAK inhibitor in CALR-mutant myelofibrosis	174
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study	174
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis	174
Role of the molecular staging and response in the management of follicular lymphoma patients	173
RBC-transfusion guidelines update	173
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2	173
Direct-Acting Antivirals During or After Immunochemotherapy in Hepatitis C Virus-Positive Diffuse Large B-Cell Lymphomas	173
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs	173
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons	171
How I treat polycythemia vera	171
Myeloproliferative Neoplasms	169
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.	169
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.	168
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients.	168
A prognostic model to predict survival in 867 WHO-defined essential thrombocythemia at diagnosis: a study by the IWG-MRT.	168
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases	167
New generation small-molecule inhibitors in myeloproliferative neoplasms	167
Disease anticipation in familial myeloproliferative neoplasms.	167
Clinical Predictors of Outcome in MPN	167
Cardiovascular events and intensity of treatment in polycythemia vera	167
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis	167
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.	166
Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma	166
Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.	165
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group	165
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis	165
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)	164
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy	164
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report	164
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.	164
New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms	164
Stem cell transplant in MF: It’s time to personalize	164
A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!	164
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment	162
Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies	162
Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis	162
Exaggerated insect bite-like reaction in patients affected by oncohaematological diseases	162
Totale	18.594

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	160.654
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	160.654

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	3.299	0	0	0	0	0	540	333	419	645	298	438	626
2021/2022	2.587	335	436	24	118	96	128	150	159	146	416	243	336
2022/2023	2.444	283	79	141	230	177	650	15	300	372	82	40	75
2023/2024	6.571	1.015	1.045	1.030	1.308	1.278	449	66	83	201	20	24	52
2024/2025	3.136	26	12	606	106	104	251	107	217	389	241	246	831
2025/2026	3.920	591	535	640	1.179	557	418	0	0	0	0	0	0
Totale													38.924